Toxicity of platinum(II) amino acid (N,O) complexes parallels their binding to DNA as measured in a new solid phase assay involving a fluorescent HMG1 protein construct readout |
| |
Authors: | Christopher J Ziegler Karen E Sandman Cynthia H Liang S J Lippard |
| |
Institution: | (1) Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA e-mail: lippard@lippard.mit.edu, US |
| |
Abstract: | The compound Pt(lysine)Cl2] (Kplatin) was previously identified in a study of platinum amino acid complexes as a potential antitumor drug candidate.
The DNA binding properties, high mobility group (HMG)-domain protein affinity for the platinated DNA, and cytotoxicity against
HeLa cells of Kplatin and three related (N,O) chelated platinum(II) amino acid complexes, Pt(arginine)Cl2] (Rplatin), KPt(Ne-acetyllysine)Cl2] (NacKplatin), and KPt(norleucine)Cl2] (Norplatin), are reported. The four complexes have identical PtCl2(N,O) coordination environments. A new solid phase screening methodology was devised in which platinated DNA probes are covalently
attached to a nylon support and tested for their ability to bind a fluorescently labeled HMG-domain protein. The fluorescent
HMG-domain protein was generated by expressing a fusion of the green fluorescent protein (GFP) with recombinant rat HMG1.
Binding revealed by the solid phase method correlated well with the results of gel mobility shift and HeLa cytotoxicity assays.
These results suggest that the net charge on the complex, rather than the nature of the side chain, is the most important
factor underlying the DNA binding properties and toxicity of amino acid (N,O) chelated platinum complexes. This property explains
why Kplatin was previously selected from the pool of platinum amino acid complexes based on the ability of its DNA adducts
to bind HMG1.
Received: 3 February 1999 / Accepted: 7 April 1999 |
| |
Keywords: | Antitumor drug Green fluorescent protein Screening method Fusion protein |
本文献已被 SpringerLink 等数据库收录! |
|